Lanthanum(Ⅲ) chloride

Synonyms: Lanthanum trichloride
Lanthanum (Ⅲ) chloride (Lanthanum trichloride) 是一种口服有效、可穿透血脑屏障的抗肿瘤增敏剂和肾脏保护剂,但具有明确的神经毒性,它通过抑制 PI3K/Akt 生存通路和 DNA 损伤修复蛋白 RAD51 逆转癌细胞对 Cisplatin (MS-E94993) 的耐药性,通过抑制 ERK/MSK1/CREB 信号通路和破坏 LKB1 介导的轴突发育通路导致突触和轴突结构异常并最终损害海马依赖的学习和记忆功能,同时通过改变 nHAp (MS-N19887) 的形态抑制其诱导的线粒体自噬 (mitophagy) 和线粒体介导的细胞凋亡 (apoptosis) 从而发挥肾脏保护作用。
产品编号: MS-G98850 纯度: 99.99% CAS No.: 10099-58-8 分子式: LaCl3 分子量: 245.27
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5g
询价
3-5 天
10g
询价
3-5 天
25g
询价
3-5 天
50g
询价
3-5 天
100g
询价
3-5 天
500g
询价
3-5 天
> 100g
询价
询价

产品描述

Lanthanum (Ⅲ) chloride (Lanthanum trichloride) 是一种口服有效、可穿透血脑屏障的抗肿瘤增敏剂和肾脏保护剂,但具有明确的神经毒性,它通过抑制 PI3K/Akt 生存通路和 DNA 损伤修复蛋白 RAD51 逆转癌细胞对 Cisplatin (MS-E94993) 的耐药性,通过抑制 ERK/MSK1/CREB 信号通路和破坏 LKB1 介导的轴突发育通路导致突触和轴突结构异常并最终损害海马依赖的学习和记忆功能,同时通过改变 nHAp (MS-N19887) 的形态抑制其诱导的线粒体自噬 (mitophagy) 和线粒体介导的细胞凋亡 (apoptosis) 从而发挥肾脏保护作用。

生物实验数据

生物活性 Lanthanum (Ⅲ) chloride (Lanthanum trichloride) is an orally effective, blood-brain barrier-penetrating antitumor sensitizer and renoprotective agent with explicit neurotoxicity that reverses cancer cell resistance to Cisplatin (MS-E94993) by inhibiting the PI3K/Akt survival pathway and the DNA damage repair protein RAD51, induces synaptic and axonal structural abnormalities and ultimately impairs hippocampus-dependent learning and memory by inhibiting the ERK/MSK1/CREB signaling pathway and disrupting the LKB1-mediated axon development pathway, and exerts renoprotective effects by altering the morphology of nHAp (MS-N19887) to inhibit its induced mitophagy and mitochondria-mediated apoptosis.
体外研究
(In Vitro)

Lanthanum (Ⅲ) chloride (0.025-1 mM; 24 h) 可呈剂量依赖性降低原代培养大鼠大脑皮质神经元的活力。
Lanthanum (Ⅲ) chloride (0.025-0.1 mM) 可剂量依赖性地缩短原代培养大鼠大脑皮层神经元的平均神经突长度和最长神经突 (轴突) 长度。
Lanthanum (Ⅲ) chloride (0.025-0.1 mM) 可剂量依赖性地下调原代培养大鼠大脑皮层神经元中 LKB1、p-LKB1、STRAD、MO25、MARK2、α-tubulin、STK25 和 GM130 的蛋白水平,以及 p-MARK2/MARK2 和 Tyr/Ace 比值。
Lanthanum (Ⅲ) chloride (0.025-0.1 mM) 可剂量依赖性地降低原代培养大鼠大脑皮层神经元中 LKB1 和 STRAD 的蛋白表达水平及其共定位。
Lanthanum (Ⅲ) chloride (0.1 mM) 诱导原代培养大鼠大脑皮层神经元中 p-MARK2 和 Tyr 蛋白表达下调的效应可被 LKB1 过表达缓解。
Lanthanum (Ⅲ) chloride 诱导的原代培养大鼠大脑皮层神经元平均神经突长度及最长神经突 (轴突) 长度的缩短可通过 LKB1 过表达得到缓解。
Lanthanum (Ⅲ) chloride (0.5-3 µM; 48 h) 浓度 ≥ 2 µM 时可降低人卵巢癌细胞 SKOV3 和 SKOV3/DDP 的细胞存活率,且对 SKOV3/DDP 细胞的细胞毒性更强,而浓度 ≤ 1.5 µM 时不会显著降低细胞存活率。
Lanthanum (Ⅲ) chloride (1.5 µM; 24-72 h) 在共孵育 48 或 72 h 时可增强顺铂对人卵巢癌细胞 SKOV3 和 SKOV3/DDP 的细胞毒性。
Lanthanum (Ⅲ) chloride (1.5 µM; 48 h) 可增强 Cisplatin 诱导的 SKOV3 和 SKOV3/DDP 人卵巢癌细胞凋亡,共孵育 48 h。
Lanthanum (Ⅲ) chloride (1.5 µM; 48 h) 调控人卵巢癌细胞 SKOV3 和 SKOV3/DDP 中凋亡相关蛋白的表达,上调 Bax 和 Cleaved-caspase 3 水平并下调 Bcl-2 水平。
Lanthanum (Ⅲ) chloride (1.5 µM; 48 h) 可抑制顺铂诱导的 RAD51 表达,并在与顺铂共孵育 48 h 后灭活 SKOV3 和 SKOV3/DDP 人卵巢癌细胞中的 PI3K/Akt 通路。
Lanthanum (Ⅲ) chloride (1.5 µM; 48 h) 可增强顺铂诱导的细胞毒性,并通过抑制 PI3K/Akt 通路降低人卵巢癌细胞 SKOV3 和 SKOV3/DDP 中的 RAD51 表达,而 Akt 激活剂 SC79 可逆转这些效应。
Lanthanum (Ⅲ) chloride (0-65 μM; 24 h) 被测试其对 HK-2 细胞活力的影响,但未提供明确的定量存活数据。
Lanthanum (Ⅲ) chloride (60 μM; 72 h) 可显著保护 nHAp 诱导的 HK-2 细胞中的线粒体形态与数量,其线粒体绿色荧光探针 (Mito-Tracker Green) 荧光强度相较于 nHAp 诱导模型组有所升高。
Lanthanum (Ⅲ) chloride (60 μM; 72 h) 可显著维持纳米羟基磷灰石 (nHAp) 诱导的 HK-2 细胞的线粒体膜电位,相较于 nHAp 诱导模型组,其能减少 JC-1 向单体形式的转变。
Lanthanum (Ⅲ) chloride (60 μM; 72 h) 可显著抑制 nHAp 诱导的 HK-2 细胞凋亡。
Lanthanum (Ⅲ) chloride (60 μM; 72 h) 可显著降低 nHAp 诱导的 HK-2 细胞 DNA 双链断裂,表现为与模型组相比 γ-H2AX 荧光强度降低。
Lanthanum (Ⅲ) chloride (15-60 μM; 72 h) 可逆转 nHAp 诱导的 HK-2 细胞凋亡相关蛋白表达变化,上调 Bcl-2 水平并下调 Bax 及 Cleaved Caspase-3 水平。
Lanthanum (Ⅲ) chloride (15-60 μM; 72 h) 可抑制 nHAp 诱导的 HK-2 细胞线粒体自噬,降低 LC3B-II/I 比值并上调 P62 表达。
Lanthanum (Ⅲ) chloride (60 μM; 72 h) 可抑制 nHAp 诱导的 HK-2 细胞中 mPTP 开放,与模型组相比可增强钙黄绿素 AM 的荧光强度。
Lanthanum (Ⅲ) chloride (60 μM; 72 h) 可减轻 nHAp 诱导的 HK-2 细胞线粒体损伤及凋亡小体形成,该结果通过透射电镜观察得到。

Cell Viability Assay

Cell Line: human ovarian cancer SKOV3 and SKOV3/DDP cells
Concentration: 0.5, 1, 1.5, 2, 2.5, 3 µM
Incubation Time: 48 h
Result: Resulted in >90% cell survival in both SKOV3 and SKOV3/DDP cells at 0.5, 1, and 1.5 µM.
Caused <90% cell survival at concentrations ≥2 µmol/L, with a higher percentage of dead cells in SKOV3/DDP cells compared to SKOV3 cells.

Cell Viability Assay

Cell Line: human ovarian cancer SKOV3 and SKOV3/DDP cells
Concentration: 1.5 µM (combined with Cisplatin at 5 µM for SKOV3 cells or 15 µM for SKOV3/DDP cells)
Incubation Time: 24, 48, 72 h
Result: Reduced cell survival compared to cisplatin alone at 48 and 72 h in SKOV3 cells.
Reduced cell survival compared to cisplatin alone at 48 and 72 h in SKOV3/DDP cells.

Apoptosis Analysis

Cell Line: human ovarian cancer SKOV3 and SKOV3/DDP cells
Concentration: 1.5 µM (combined with Cisplatin at 5 µM for SKOV3 cells or 15 µM for SKOV3/DDP cells)
Incubation Time: 48 h
Result: Increased the apoptotic cell percentage compared to cisplatin alone in SKOV3 cells.
Increased the apoptotic cell percentage compared to cisplatin alone in SKOV3/DDP cells.

Western Blot Analysis

Cell Line: human ovarian cancer SKOV3 and SKOV3/DDP cells
Concentration: 1.5 µM (combined with Cisplatin at 5 µM for SKOV3 cells or 15 µM for SKOV3/DDP cells)
Incubation Time: 48 h
Result: Further increased the protein levels of Bax and Cleaved-caspase 3 compared to cisplatin alone.
Decreased the protein level of Bcl-2 compared to cisplatin alone.\n
Reduced the cisplatin-induced increase in RAD51 protein levels compared to cisplatin alone.
Reduced the cisplatin-induced increase in phosphorylated PI3K (p-PI3K) and phosphorylated Akt (p-Akt) protein levels compared to cisplatin alone.

Cell Viability Assay

Cell Line: human renal tubular epithelial HK-2 cells
Concentration: 0, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65 μM
Incubation Time: 24 h
Result: Reported no explicit quantitative cell survival rate values for specific concentrations.

Apoptosis Analysis

Cell Line: nHAp-induced human renal tubular epithelial HK-2 cells
Concentration: 60 μM
Incubation Time: 48 h (pre-incubation prior to 24 h nHAp incubation)
Result: Reduced the apoptosis rate of nHAp-induced HK-2 cells from 37.8% to 10.1%, a significant decrease relative to the model group.

Immunofluorescence

Cell Line: nHAp-induced human renal tubular epithelial HK-2 cells
Concentration: 60 μM
Incubation Time: 48 h (pre-incubation prior to 24 h nHAp incubation)
Result: Significantly reduced γ-H2AX green fluorescence intensity in nHAp-induced HK-2 cells.

Western Blot Analysis

Cell Line: nHAp-induced human renal tubular epithelial HK-2 cells
Concentration: 15, 30, 60 μM
Incubation Time: 48 h (pre-incubation prior to 24 h nHAp incubation)
Result: Reversed nHAp-induced changes in protein expression: increased Bcl-2 expression, while decreased Bax and Cleaved Caspase-3 expression, with effects observed across 15, 30, and 60 μM concentrations.

Western Blot Analysis

Cell Line: nHAp-induced human renal tubular epithelial HK-2 cells
Concentration: 15, 30, 60 μM
Incubation Time: 48 h (pre-incubation prior to 24 h nHAp incubation)
Result: Reversed nHAp-induced changes in mitophagy-related proteins: decreased the LC3B-II/I ratio, while increased P62 expression, with the 30 μmol/L dose showing superior efficacy.
体内研究
(In Vivo)

Lanthanum (Ⅲ) chloride (0.25-1.00%;口服 (饮水);持续给药;从出生至断奶后 2 个月) 暴露会以剂量依赖的方式损伤 Wistar 幼鼠的空间学习与记忆能力。
Lanthanum (Ⅲ) chloride (0.125-0.5%;口服;经母鼠饮水暴露;从受孕至出生后第 21 天) 导致仔鼠海马区出现剂量依赖性轴突异常,并下调 LKB1-MARK2 与 LKB1-STK25-GM130 信号通路。
Lanthanum (Ⅲ) chloride (0.03-0.3 ng/kg;静脉注射;每 3 天 1 次;持续 8 周) 可减轻 Wistar 大鼠的慢性肾脏病 (CKD) 肾损伤,其中 0.1 ng/kg 剂量在逆转线粒体自噬及线粒体介导的凋亡标志物方面展现出更优的效果。

Animal Model: Wistar (pups, exposed from birth through maternal lactation then direct oral ingestion; parental rats weighed 240-260 g)
Dosage: 0.25% (18 mM); 0.50% (36 mM); 1.00% (72 mM)
Administration: oral (drinking water); continuous; from birth to 2 months post-weaning
Result: Impaired spatial learning and memory in Wistar rat pups in a dose-dependent manner, with the highest dose (1.00% in drinking water) reducing target quadrant crossings to ~0.5 and phosphorylated MSK1 levels to 32.52% of control.
Animal Model: Offspring of adult female rats (sourced from Experimental Animal Center of China Medical University)
Dosage: 0.125%; 0.25%; 0.5%
Administration: p.o.; continuous ad libitum; conception to postnatal day 21
Result: Caused dose-dependent reductions in the number and length of axons in the hippocampal CA1 region.
Ruptured and twisted axons into clusters, losing continuous linear morphology at the 0.5% dose.
Induced chaotic distribution of apical dendrites and dose-dependent decrease in mossy fiber number in the hippocampal CA3 region.
Significantly reduced the expression of LKB1, p-LKB1, STRAD, MO25, MARK2, α-tubulin, STK25, and GM130 proteins.
Significantly reduced the ratio of p-MARK2 to MARK2 and the ratio of Tyr to Ace.
Animal Model: Wistar rats (6-week-old male, 200 g weight, induced by 2% adenine suspension and high-phosphorus diet)
Dosage: 0.03 ng/kg; 0.1 ng/kg; 0.3 ng/kg
Administration: i.v.; every 3 days; 8 weeks
Result: Increased rat body weight to varying degrees relative to model group.
Did not affect serum phosphorus and calcium levels.
Reduced glomerular dilation, mesangial cell proliferation, renal tubular epithelial degeneration, and collagen fiber deposition/fibrosis relative to model group.
Elevated Bcl-2 protein expression, with significant increase at 0.1 ng/kg dose relative to model group.
Significantly reduced Bax protein expression across all doses relative to model group.
Significantly reduced Cleaved Caspase-3 protein expression across all doses relative to model group.
Significantly reduced LC3B-II/I protein expression across all doses relative to model group.
Significantly elevated P62 protein expression across all doses relative to model group.
Reduced mitochondrial damage and fewer apoptotic bodies in renal cells relative to model group.
性状 固体
颜色 White to off-white

化学信息

分子量 245.27
分子式 LaCl3
CAS No. 10099-58-8
别名 Lanthanum trichloride

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : 2 mg/mL (8.15 mM; 超声助溶)

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O1 mM4.0771 mL20.3857 mL40.7714 mL101.9285 mL
5 mM0.8154 mL4.0771 mL8.1543 mL20.3857 mL

* 备注:如您选择水作为储备液,请稀释至工作液后,再用 0.22 μm 的滤膜过滤除菌后使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础